Ultrasound Measurement of Quadriceps Shortening During Neuromuscular Electrical Stimulation in Critically Ill Patients
Completed
- Conditions
- Quadriceps Muscle AtrophyICU Acquired Weakness
- Registration Number
- NCT04722445
- Lead Sponsor
- Groupe Hospitalier du Havre
- Brief Summary
ICU-Aw is highly prevalent (50%) among critically ill patients. Its diagnosis is usually delayed as it requires patients' awakening and collaboration to provide accurate measurement.
This study aims to investigate the accuracy of an early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation to diagnose future ICU-Aw in critically ill patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Mechanical ventilation for at least 24 hours
Exclusion Criteria
- Decision to withhold life-sustaining treatment
- Pregnancy
- Degenerative neurological pathology with disabling muscle weakness
- Pace Maker
- Inability to communicate
- Chronic loss of autonomy described by the patient's family
- Guardianship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ICU-Aw diagnosis In the 24 hours following extubation Measured with the Medical Research Council score (scored 0 (minimum) to 60 (maximum); with a score \< 48 meaning ICU-acquired weakness)
- Secondary Outcome Measures
Name Time Method Cough capacity In the 30 minutes before extubation (during spontaneous breathing trial) Peak Cough Flow
Respiratory muscles strength In the 30 minutes before extubation (during spontaneous breathing trial) Maximal Inspiratory Pressure and Maximal Expiratory Pressure
Extubation failure/success Within 48 hours after extubation Reintubation or death
Trial Locations
- Locations (1)
Groupe Hospitalier du Havre
🇫🇷Montivilliers, France